Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy

Journal of Allergy and Clinical Immunology

Volumn 118, Issue 6, 2006, Pages 1369-1374

  Williamson, Mike P ^a   McCormick, Theron G ^b   Nance, Christina L ^b   Shearer, William T ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

CD4; EGCG; flow cytometry; gp120; HIV 1; NMR; STD

Indexed keywords

CD4 ANTIGEN; EPIGALLOCATECHIN GALLATE; POLYPHENOL DERIVATIVE; T LYMPHOCYTE RECEPTOR;

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TEA;

ANTIGENS, CD4; BINDING SITES; CATECHIN; CD4 IMMUNOADHESINS; FLAVONOIDS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PHENOLS; PROTEASE INHIBITORS; RECEPTORS, HIV; TEA;

EID: 33845222645     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2006.08.016     Document Type: Article

References (36)

1. Janeway Jr. C.A., Carding S., Jones B., Murray J., Portoles P., Rasmussen R., et al. CD4+ T cells: specificity and function. Immunol Rev 101 (1988) 39-80
2. D'Souza M.P., Cairns J.S., and Plaeger S.F. Current evidence and future directions for targeting HIV entry: therapeutic and prophylactic strategies. JAMA 284 (2000) 215-222
3. NCI. Clinical development plan: tea extracts: green tea polyphenols: epigallocatechin gallate. J Cell Biochem 26 (1996) 236-257
4. Yamaguchi K., Honda M., Ikigai H., Hara Y., and Shimamura T. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res 53 (2002) 19-34
5. Fassina G., Buffa A., Benelli R., Varnier O.E., Noonan D.M., and Albini A. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent. AIDS 16 (2002) 939-941
6. Deana R., Turetta L., Donella-Deana A., Dona M., Brunati A.M., De Michiel L., et al. Green tea epigallocatechin-3-gallate inhibits platelet signalling pathways triggered by both proteolytic and non-proteolytic agonists. Thromb Haemost 89 (2003) 866-874
7. Ludwig A., Lorenz M., Grimbo N., Steinle F., Meiners S., Bartsch C., et al. The tea flavonoid, epigallocatechin-3-gallate, reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. Biochem Biophys Res Commun 316 (2004) 659-665
8. Jöbstl E., O'Connell J., Fairclough J.P., and Williamson M.P. Molecular model for astringency produced by polyphenol/protein interactions. Biomacromolecules 5 (2004) 942-949
9. Sakata R., Ueno T., Nakamura T., Sakamoto M., Torimura T., and Sata M. Green tea polyphenol, epigallocatechin-3-gallate, inhibits platelet-derived growth factor-induced proliferation of human hepatic stellate cell line LI90. J Hepatol 40 (2004) 52-59
10. Charlton A.J., Haslam E., and Williamson M.P. Multiple conformations of the proline-rich protein/epigallocatechin gallate complex determined by time-averaged nuclear Overhauser effects. J Am Chem Soc 124 (2002) 9899-9905
11. Wang Y.C., and Bachrach U. The specific anti-cancer activity of green tea (-)-epigallocatechin-3-gallate (EGCG). Amino Acids 22 (2002) 131-143
12. Nakane H., and Ono K. Differential inhibition of HIV-reverse transcriptase and various DNA and RNA polymerases by some catechin derivatives. Nucleic Acids Symp Ser 21 (1989) 115-116
13. Kawai K., Tsuno N.H., Kitayama J., Okaji Y., Yazawa K., Asakage M., et al. Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding. J Allergy Clin Immunol 112 (2003) 951-957
14. Liu S., Lu H., Zhao Q., He Y., Niu J., Debnath A.K., et al. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta 1723 (2005) 270-281
15. Nance C., Williamson M., McCormick T., and Shearer W. Binding of the green tea polyphenol, epigallocatechin gallate, to the CD4 receptor on human CD4+T cells resulting in inhibition of HIV-1-gp120 binding. Clin Immunol 115 (2005) S245
16. Jacobson J., Israel R., Lowy I., Ostrow N., Vassilatos L., Barish M., et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 48 (2004) 423-429
17. Machius M. Structural biology: a high-tech tool for biomedical research. Curr Opin Nephrol Hypertens 12 (2003) 431-438
18. Charlton A.J., Baxter N.J., Khan M.L., Moir A.J., Haslam E., Davies A.P., et al. Polyphenol/peptide binding and precipitation. J Agric Food Chem 50 (2002) 1593-1601
19. Mayer M., and Meyer B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc 123 (2001) 6108-6117
20. Benie A.J., Moser R., Bauml E., Blaas D., and Peters T. Virus-ligand interactions: identification and characterization of ligand binding by NMR spectroscopy. J Am Chem Soc 125 (2003) 14-15
21. Meyer B., and Peters T. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew Chem Int Ed Engl 42 (2003) 864-890
22. Wu H., Myszka D.G., Tendian S.W., Brouillette C.G., Sweet R.W., Chaiken I.M., et al. Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding. Proc Natl Acad Sci U S A 93 (1996) 15030-15035
23. Arthos J., Deen K.C., Chaikin M.A., Fornwald J.A., Sathe G., Sattentau Q.J., et al. Identification of the residues in human CD4 critical for the binding of HIV. Cell 57 (1989) 469-481
24. Nance C.L., and Shearer W.T. Is green tea good for HIV-1 infection?. J Allergy Clin Immunol 112 (2003) 851-853
25. Hamza A., and Zhan C.G. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? mechanistic insights from computer modeling and the implication for rational design of anti-HIV-1 entry inhibitors. J Phys Chem B 110 (2006) 2910-2917
26. Lee M., Wang Z., Li H., Chen L., Sun Y., Gobbo S., et al. Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol Biomarkers Prev 4 (1995) 393-399
27. Myszka D.G., Sweet R.W., Hensley P., Brigham-Burke M., Kwong P.D., Hendrickson W.A., et al. Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A 97 (2000) 9026-9031
28. Patterson L.J., Aberdeen A., Kone J., Haben M., Raymond M., and Berkower I. Formation of HIV-1 envelope-hepatitis B core antigen hybrids with high affinity for CD4. Biochem Biophys Res Commun 285 (2001) 639-643
29. Gelderblom H.R., Hausmann E.H., Ozel M., Pauli G., and Koch M.A. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology 156 (1987) 171-176
30. Zhu P., Chertova E., Bess Jr. J., Lifson J.D., Arthur L.O., Liu J., et al. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A 100 (2003) 15812-15817
31. Lee M.J., Maliakal P., Chen L., Meng X., Bondoc F.Y., Prabhu S., et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 11 (2002) 1025-1032
32. Behr M., and Small P. Inhibition of carcinogenesis by tea. Nature 389 (1997) 134-135
33. Lambert J.D., and Yang C.S. Mechanisms of cancer prevention by tea constituents. J Nutr 133 (2003) 3262S-3267S
34. Lipton S.A. Turning down, but not off. Nature 428 (2004) 473
35. Beliveau R., and Gingras D. Green tea: prevention and treatment of cancer by nutraceuticals. Lancet 364 (2004) 1021-1022
36. Nakachi K., Matsuyama S., Miyake S., Suganuma M., and Imai K. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors 13 (2000) 49-54